Microbiotica advances two microbiome drugs to phase 1

Microbiotica has received regulatory approval to move forward on Phase 1b clinical trials for its microbiome medicines. The UK-based company is investigating how microbiome modulation could improve the efficacy of immune checkpoint inhibitors (ICIs) like Keytruda, used for treating cancers like melanoma. The trial will test MB097, consisting of a group of bacteria identified to boost the response to ICIs, against advanced melanoma. Other companies in the field include Seres Therapeutics, Maat Pharma, and Microba.